{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:01:57Z","timestamp":1791925317743,"version":"4.3.4"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T00:00:00Z","timestamp":1556582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.ijid.2019.04.028","type":"journal-article","created":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T11:43:32Z","timestamp":1557834212000},"page":"74-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Linezolid interruption in patients with fluoroquinolone-resistant tuberculosis receiving a bedaquiline-based treatment regimen"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2596-2786","authenticated-orcid":false,"given":"Olatunde","family":"Olayanju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliasgar","family":"Esmail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Limberis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phindile","family":"Gina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7709-5341","authenticated-orcid":false,"given":"Keertan","family":"Dheda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijid.2019.04.028_bib0005","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12941-016-0156-y","article-title":"Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis","volume":"15","author":"Agyeman","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"1","key":"10.1016\/j.ijid.2019.04.028_bib0010","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/FTD.0b013e3181cc6d6f","article-title":"Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis","volume":"32","author":"Alffenaar","year":"2010","journal-title":"Ther Drug Monit"},{"issue":"4","key":"10.1016\/j.ijid.2019.04.028_bib0015","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/jac\/dkq017","article-title":"Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000\u201306","volume":"65","author":"Anger","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.ijid.2019.04.028_bib0020","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1183\/13993003.00606-2015","article-title":"Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study","volume":"46","author":"Bolhuis","year":"2015","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.ijid.2019.04.028_bib0025","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00387-2017","article-title":"Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR-and XDR-TB: a multicentre study","volume":"49","author":"Borisov","year":"2017","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.ijid.2019.04.028_bib0030","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/thx.2006.058867","article-title":"Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection","volume":"61","author":"Breen","year":"2006","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.ijid.2019.04.028_bib0035","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.ijantimicag.2015.09.002","article-title":"Linezolid-related adverse events predictive score (LAPS): Usefulness in clinical practice","volume":"46","author":"Buzel\u00e9","year":"2015","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"10.1016\/j.ijid.2019.04.028_bib0040","doi-asserted-by":"crossref","first-page":"447","DOI":"10.5588\/ijtld.11.0451","article-title":"Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"16","author":"Cox","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"issue":"4","key":"10.1016\/j.ijid.2019.04.028_bib0045","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S2213-2600(17)30079-6","article-title":"The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis","volume":"5","author":"Dheda","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.ijid.2019.04.028_bib0050","first-page":"432","article-title":"Factors associated with time to sputum smear conversion in active pulmonary tuberculosis","volume":"7","author":"Dominguez-Castellano","year":"2003","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"10.1016\/j.ijid.2019.04.028_bib0055","doi-asserted-by":"crossref","first-page":"290","DOI":"10.5588\/ijtld.15.0490","article-title":"Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults","volume":"20","author":"Furin","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"10.1016\/j.ijid.2019.04.028_bib0060","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01799-2016","article-title":"Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis","volume":"49","author":"Guglielmetti","year":"2017","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.ijid.2019.04.028_bib0065","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1742-1241.2006.01131.x","article-title":"Factors influencing sputum smear and culture conversion time among patients with new case pulmonary tuberculosis","volume":"61","author":"G\u00fcler","year":"2007","journal-title":"Int J Clin Pract"},{"issue":"6","key":"10.1016\/j.ijid.2019.04.028_bib0070","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ijantimicag.2017.01.017","article-title":"Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis","volume":"49","author":"Kamp","year":"2017","journal-title":"Int J Antimicrob Agents"},{"issue":"16","key":"10.1016\/j.ijid.2019.04.028_bib0075","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","article-title":"Linezolid for treatment of chronic extensively drug-resistant tuberculosis","volume":"367","author":"Lee","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ijid.2019.04.028_bib0080","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1365-2125.2007.03034.x","article-title":"Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV\/AIDS prevalence: prospective observational study","volume":"65","author":"Mehta","year":"2008","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.ijid.2019.04.028_bib0085","first-page":"121","article-title":"Adverse events to first line anti-tuberculosis drugs in patients","volume":"14","author":"Michael","year":"2016","journal-title":"Ann Ib Postgrad Med"},{"key":"10.1016\/j.ijid.2019.04.028_bib0090","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00544-2018","article-title":"Long term bedaquiline-related treatment outcomes in patients with extensively drug resistant tuberculosis from South Africa","author":"Olayanju","year":"2018","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.ijid.2019.04.028_bib0095","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/jac\/dkl298","article-title":"Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis","volume":"58","author":"Park","year":"2006","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.ijid.2019.04.028_bib0100","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1183\/09031936.00022912","article-title":"Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis","volume":"40","author":"Sotgiu","year":"2012","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.ijid.2019.04.028_bib0105","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1183\/09031936.00035114","article-title":"Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China","volume":"45","author":"Tang","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijid.2019.04.028_bib0110","series-title":"CTCAE v3. 0: development of a comprehensive grading system for the adverse effects of cancer treatment. Paper presented at the Seminars in radiation oncology","author":"Trotti","year":"2003"},{"key":"10.1016\/j.ijid.2019.04.028_bib0115","series-title":"Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control","author":"WHO","year":"2006"},{"key":"10.1016\/j.ijid.2019.04.028_bib0120","series-title":"Definitions and reporting frameworks for tuberculosis- 2013 revision (updated December 2014)","author":"WHO","year":"2013"},{"key":"10.1016\/j.ijid.2019.04.028_bib0125","series-title":"Rapid Communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis","first-page":"1","author":"WHO","year":"2018"},{"issue":"4","key":"10.1016\/j.ijid.2019.04.028_bib0130","first-page":"603","article-title":"Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis","volume":"7","author":"Zhang","year":"2015","journal-title":"J Thorac Dis"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971219301997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971219301997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:45:13Z","timestamp":1761119113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971219301997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":26,"alternative-id":["S1201971219301997"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2019.04.028","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Linezolid interruption in patients with fluoroquinolone-resistant tuberculosis receiving a bedaquiline-based treatment regimen","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2019.04.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}